PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

[1]  N. Hardcastle,et al.  Impact of operability and total metastatic ablation on outcomes after stereotactic ablative radiotherapy (SABR) for oligometastases. , 2022, International journal of radiation oncology, biology, physics.

[2]  B. Yaremko,et al.  Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET) - Extended Long-Term Outcomes. , 2022, International journal of radiation oncology, biology, physics.

[3]  Zhenhua Zhao,et al.  Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis , 2022, European Radiology.

[4]  C. Belka,et al.  18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study , 2022, The Journal of Nuclear Medicine.

[5]  A. P. Caresia-Aróztegui,et al.  Utilidad de los radioligandos PSMA en el diagnóstico y tratamiento del carcinoma de próstata , 2022, Revista Española de Medicina Nuclear e Imagen Molecular.

[6]  V. Rangarajan,et al.  Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Peter J Scott,et al.  PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study , 2021, The Journal of Nuclear Medicine.

[8]  F. Bray,et al.  Epidemiology and Prevention of Prostate Cancer. , 2021, European urology oncology.

[9]  S. Shariat,et al.  Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis , 2021, BJU international.

[10]  Mingxing Huang,et al.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis , 2021, Frontiers in Oncology.

[11]  P. Carroll,et al.  A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  H. Moch,et al.  What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  S. Fanti,et al.  Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer , 2021, The Journal of Nuclear Medicine.

[14]  C. Stief,et al.  Radiotherapy of oligometastatic prostate cancer: a systematic review , 2021, Radiation oncology.

[15]  R. Bristow,et al.  Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. , 2021, European urology.

[16]  B. Tran,et al.  PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going? , 2021, Therapeutic advances in medical oncology.

[17]  I. de Kouchkovsky,et al.  Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review , 2020, Translational andrology and urology.

[18]  A. Kishan,et al.  A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). , 2020, European urology.

[19]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[20]  H. Weir,et al.  Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017 , 2020, MMWR. Morbidity and mortality weekly report.

[21]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[22]  W. Oyen,et al.  Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Udochukwu Oyoyo,et al.  PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. , 2020, Radiology.

[24]  Ash A. Alizadeh,et al.  Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.

[25]  H. G. van der Poel,et al.  Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. , 2020, European urology oncology.

[26]  Ida Sonni,et al.  Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study , 2020, The Journal of Nuclear Medicine.

[27]  L. Livi,et al.  Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis. , 2020, European urology oncology.

[28]  N. Lawrentschuk,et al.  Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.

[29]  J. Yaxley,et al.  The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy , 2019, Prostate Cancer and Prostatic Diseases.

[30]  M. Graefen,et al.  External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. , 2019, European urology.

[31]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[32]  P. Ost,et al.  Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT. , 2019, European journal of cancer care.

[33]  H. G. van der Poel,et al.  Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.

[34]  J. Fütterer,et al.  A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. , 2019, European urology oncology.

[35]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[36]  A. Kishan,et al.  Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT). , 2018, International journal of radiation oncology, biology, physics.

[37]  A. Costello,et al.  Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial , 2019, International journal of cancer.

[38]  T. Eade,et al.  Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. , 2018, European urology oncology.

[39]  Minsong Cao,et al.  Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[40]  N. Lawrentschuk,et al.  Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. , 2018, European urology.

[41]  Chong Hyun Suh,et al.  Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. , 2018, European urology.

[42]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[43]  M. Cooperberg,et al.  The use of PET/CT in prostate cancer , 2018, Prostate Cancer and Prostatic Diseases.

[44]  R. Breau,et al.  Follow-up Care for Survivors of Prostate Cancer - Clinical Management: a Program in Evidence-Based Care Systematic Review and Clinical Practice Guideline. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[45]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[46]  J. Yaxley,et al.  The use of 68 Ga‐PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer , 2016, BJU international.

[47]  Suzanne B. Stewart-Merrill,et al.  Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? , 2016, The Journal of urology.

[48]  M. Fabrini,et al.  [18F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results , 2016, Radiation oncology.

[49]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[50]  P. Sèbe,et al.  [Elevation of PSA after prostate radiotherapy: rebound or biochemical recurrence?]. , 2008, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[51]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[52]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[53]  W. J. Morris,et al.  Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma , 2002, Cancer.